Skye Bioscience, INC. (SKYE) — SEC Filings

Overview

Skye Bioscience, INC. (SKYE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 16, 2026: Skye Bioscience, Inc. filed a Definitive Additional Materials (DEFA14A) on April 16, 2026. This filing includes proxy soliciting materials, likely related to upcoming shareholder votes or corporate actions. The company is based in San Diego, California, and operates in the Pharmaceutical Preparation

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Skye Bioscience, INC. is neutral.

Filing Type Overview

Skye Bioscience, INC. (SKYE) has filed 1 4, 1 ARS, 1 DEFA14A, 1 PREM14A, 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 3 SC 13G, 1 S-1/A, 1 S-1, 2 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• ARS Filing — ARS · Apr 16, 2026
• Skye Bioscience Files Definitive Proxy Materials — DEFA14A · Apr 16, 2026 Risk: medium
  Skye Bioscience, Inc. filed a Definitive Additional Materials (DEFA14A) on April 16, 2026. This filing includes proxy soliciting materials, likely related to up
• PREM14A Filing — PREM14A · Apr 6, 2026
• 4 Filing — 4 · Apr 2, 2026
• 8-K Filing — 8-K · Dec 23, 2025
• Skye Bioscience's Losses Mount Amid R&D Surge, Nimacimab Fails Phase 2a — 10-Q · Nov 10, 2025 Risk: high
  Skye Bioscience, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $41,482,851, a substantial rise from $1
• Skye Bioscience Files 8-K — 8-K · Oct 6, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on October 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Skye Bioscience Losses Widen Amid R&D Push — 10-Q · Aug 7, 2025 Risk: high
  Skye Bioscience, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue stage as a pharmaceutical company. T
• Skye Bioscience Files 8-K: Accountant, Shareholder Votes, Exhibits — 8-K · Jun 11, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on June 11, 2025, reporting on events that occurred on June 6, 2025. The filing indicates changes in the registrant's certify
• Skye Bioscience Q1 2025 10-Q Filed — 10-Q · May 8, 2025 Risk: medium
  Skye Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the first quarter of 2025, detailing its a
• Skye Bioscience Files Definitive Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
  Skye Bioscience, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting. The company, formerly known as Emerald Bioscience, Inc. an
• Skye Bioscience Files 2024 10-K — 10-K · Mar 20, 2025 Risk: medium
  Skye Bioscience, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Emerald Biosc
• Skye Bioscience Files 8-K on Director/Officer Changes — 8-K · Feb 26, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on February 26, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compensato
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Skye Bioscience Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Skye Bioscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key financial fig
• Skye Bioscience Appoints New CMO, Director — 8-K · Oct 29, 2024 Risk: medium
  Skye Bioscience, Inc. announced on October 28, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Ms. Sarah Chen to its B
• Skye Bioscience Files 8-K: Director Changes & Officer Compensation — 8-K · Oct 24, 2024 Risk: medium
  Skye Bioscience, Inc. filed an 8-K on October 24, 2024, reporting on the departure of a director, election of a new director, and a compensatory arrangement for
• Skye Bioscience Files Definitive Proxy Statement — DEF 14A · Sep 23, 2024 Risk: low
  Skye Bioscience, Inc. filed a Definitive Proxy Statement (DEF 14A) on September 23, 2024. This filing provides information to shareholders regarding the company
• Skye Bioscience Appoints New CMO, Adds Directors — 8-K · Sep 4, 2024 Risk: medium
  Skye Bioscience, Inc. announced on September 3, 2024, the appointment of Dr. Michael J. Mullan as Chief Medical Officer and the election of Dr. Mullan and Ms. S
• SC 13G Filing — SC 13G · Aug 14, 2024
• Skye Bioscience Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Skye Bioscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operat
• Skye Bioscience Appoints New CMO, Adds Directors — 8-K · Jul 3, 2024 Risk: medium
  Skye Bioscience, Inc. announced on July 1, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Dr. Smith and Ms. Sarah Che
• Skye Bioscience Files 8-K — 8-K · Jun 10, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements. The company, formerly known as Emerald Bioscience, Inc. an
• Skye Bioscience, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Skye Bioscience, Inc. (SKYE) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Skye Bioscience, Inc. filed its 10-Q report for the quarterly period
• Skye Bioscience Files S-1/A Amendment — S-1/A · Apr 4, 2024 Risk: medium
  Skye Bioscience, Inc. (SKYE) filed a Amended IPO Registration (S-1/A) with the SEC on April 4, 2024. Skye Bioscience, Inc. filed an S-1/A amendment on April 4,
• Skye Bioscience Files 8-K — 8-K · Apr 3, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on April 3, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Skye Bioscience, Inc. Files S-1 Registration Statement — S-1 · Mar 27, 2024 Risk:
  Skye Bioscience, Inc. (SKYE) filed a IPO Registration (S-1) with the SEC on March 27, 2024. Skye Bioscience, Inc. (formerly Emerald Bioscience, Inc.) filed an S
• Skye Bioscience, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 22, 2024 Risk: medium
  Skye Bioscience, Inc. (SKYE) filed a Annual Report (10-K) with the SEC on March 22, 2024. Skye Bioscience, Inc. filed its 2023 Form 10-K on March 22, 2024, repo
• 5AM Partners Amends Skye Bioscience Stake Filing — SC 13D/A · Mar 13, 2024 Risk: medium
  On March 13, 2024, 5AM Partners VII, LLC, along with affiliated entities and individuals including 5AM Co-Investors II, L.P., 5AM Ventures II, L.P., 5AM Venture
• Skye Bioscience Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 13, 2024 Risk: medium
  Skye Bioscience, Inc. announced on March 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equi
• Skye Bioscience Appoints New CMO, Elects Director — 8-K · Mar 4, 2024 Risk: medium
  Skye Bioscience, Inc. announced on February 29, 2024, the appointment of Dr. Michael J. McVicar as Chief Medical Officer and the election of Dr. Robert L. T. Sm
• Skye Bioscience Files 8-K for Corporate Info Update — 8-K · Feb 12, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on February 12, 2024, to update its corporate information, including its current name and business address at 11250 El Camino
• Sphera Funds Management Takes Stake in Skye Bioscience — SC 13G · Feb 8, 2024 Risk: low
  Sphera Funds Management Ltd., a Tel Aviv-based investment firm, reported acquiring a significant stake in Skye Bioscience, Inc. (SKYE) on January 29, 2024. This
• Altium Capital Takes Significant Stake in Skye Bioscience (SKYE) — SC 13G · Feb 5, 2024
  Altium Capital Management, LP, a New York-based investment firm, reported acquiring beneficial ownership of Skye Bioscience, Inc. (SKYE) common stock as of Janu
• 5AM Partners Amends Skye Bioscience Stake, Updates Ownership Details — SC 13D/A · Jan 31, 2024
  5AM Partners VII, LLC and its affiliated entities, including 5AM CO-INVESTORS II, L.P., 5AM PARTNERS II, LLC, 5AM VENTURES II, L.P., and 5AM VENTURES VII, L.P.,
• Skye Bioscience Reports Material Agreement & Unregistered Equity Sales — 8-K · Jan 29, 2024
  Skye Bioscience, Inc. filed an 8-K on January 29, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securities."

Frequently Asked Questions